Avapritinib - Blueprint Medicines

Drug Profile

Avapritinib - Blueprint Medicines

Alternative Names: BLU 285

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic mastocytosis; Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal stromal tumours; Solid tumours; Systemic mastocytosis

Most Recent Events

  • 05 Jan 2018 Chemical structure information added
  • 10 Dec 2017 Blueprint Medicines Corporation plans to initiate a registration-enabling clinical trial of avapritinib for Systemic mastocytosis (Late-stage disease) in the first half of 2018
  • 10 Dec 2017 Blueprint Medicines plans a proof-of-concept clinical trial of avapritinib trial for Systemic mastocytosis in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top